David Coy Ross - 02 Sep 2025 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Reporting relationship: Chief Tech & Product Officer
Issuer ticker: HCAT
Reported as of: 02 Sep 2025
Net transaction value: -$11,299
SEC form: 4
Accepted by SEC: 04 Sep 2025, 18:55:09 UTC
Prior SEC filing: 25 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Benjamin Landry, as Attorney-in-Fact

Key filing fact

David Coy Ross filed Form 4 for Health Catalyst, Inc. (HCAT) on 04 Sep 2025.

Key facts

This page summarizes David Coy Ross's Form 4 filing for Health Catalyst, Inc. (HCAT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Sep 2025, 18:55.

Change

Previous filing in this sequence was filed on 25 Jun 2025.
Current net transaction value: -$11,299.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002074748 Primary reporting owner

Ross David Coy

Relationship: Chief Tech & Product Officer
Address: C/O HEALTH CATALYST, INC., 10897 SOUTH RIVER FRONT PARKWAY #300, SOUTH JORDAN
Signature: /s/ Benjamin Landry, as Attorney-in-Fact
Signature date: 04 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HCAT transaction

Common Stock

Tax liability

Transaction value: $11,299
Shares: -3,360
Change %: -1.6%
Price: $3.36
Shares after: 204,219
Date: 02 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.